Botulinum toxin type b: A double-blind, placebo controlled, safety and efficacy study in cervical dystonia

Neurology

Volumn 49, Issue 3, 1997, Pages 701-707

  Lew, Mark F ^a   Adornato, B T ^b   Duane, D D ^c   Dykstra, D D ^d   Factor, S A ^m   Massey, J M ^e   Brin, M F ^f   Jankovic, J ^g   Rodnitzky, R L ^h   Singer, C ^m   Swenson, M R ⁱ   Tarsy, D ^j   Murray, J J ^k   Koller, M ^l   Wallace, J D ^l  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b STANFORD UNIVERSITY   (United States)

^c ARIZONA STATE UNIVERSITY   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e DUKE UNIVERSITY   (United States)

^f MOUNT SINAI MEDICAL CENTER   (United States)

^g BAYLOR COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j HARVARD MEDICAL SCHOOL   (United States)

^k PRA   (United States)

^l Athena Neurosciences Inc   (United States)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN B; PLACEBO;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSTONIA; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RATING SCALE; STATISTICAL ANALYSIS; TORTICOLLIS; UTERINE CERVIX DISEASE;

EID: 0030853667     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.49.3.701     Document Type: Article

References (32)

1. Conference report, clinical use of botulinum toxin, National Institutes of Health Consensus Development Conference statement. Arch Neurol 1991;48:1294-1298.
2. Jankovic J, Leder S, Warner I, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology 1991; 41:1088-1091.
3. Jahanshahi M, Marsden CD. Psychological functioning before and after treatment of torticollis with botulinum toxin. J Neurol Neurosurg Psychiatry 1992;55:229-231.
4. Gauthier S. Idiopathic spasmodic torticollis: pathophysiology and treatment. Can J Neurol Sci 1986;13(2):88-90.
5. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin. N Engl J Med 1991;324:1186-1194.
6. Tsui JKC, Eisen A, Calne D. Botulinum toxin in spasmodic torticollis. Adv Neurol 1988;50:593-597.
7. Tsui J, Eisen A, Stoessel AJ, et al. Double-blind study of botulinum toxin and spasmodic torticollis. Lancet 1986;ii:245-246.
8. Blackie JD, Lees AJ. Botulinum toxin treatment in spasmodic torticollis. J Neurol Neurosurg Psychiatry 1990;53:640-643.
9. Boghen D, Flanders M. Effectiveness of botulinum toxin in the treatment of spasmodic torticollis. Eur Neurol 1993;33:199-203.
10. Moore AP, Blumhardt LD. A double-blind trial of botulinum toxin "A" in torticollis with one year follow up. J Neurol Neurosurg Psychiatry 1991;54:813-816.
11. Greene P, Kang U, Fahn S, Brin M, Moskowitz C, Flaster E. Double-blind, placebo-controlled trial of botulinum toxin injections for the treatment of spasmodic torticollis. Neurology 1990;40:1213-1218.
12. Zuber M, Sebald M, Bathein N, et al. Botulinum antibodies in dystonia patients treated with type A botulinum toxin: frequency and significance. Neurology 1993;43:1715-1718.
13. Greene P, Fahn S. Development of antibodies to botulinum toxin type A in patients with torticollis treated with injections of botulinum toxin type A. In: DasGupta BR, ed. Botulinum and tetanus neurotoxin: neurotransmission and biomedical aspects. New York: Plenum Press, 1993:651-654.
14. Greene P, Fahn S, Diamond B. Development of resistance to botulinum toxin type A in patients with torticollis. Mov Disord 1994;9:213-217.
15. Jankovic J, Schwartz K. Response and immunoresistance to botulinum toxin injections. Neurology 1995;45:1743-1746.
16. Hambleton P, Moore AP. Botulinum neurotoxins: origin, structure, molecular actions, and antibodies. In: Moore P, ed. Handbook of botulinum toxin treatment. London: Blackwell Science, 1995:16-27.
17. Das Gupta BR, Sugiyama H. Molecular form of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect Immunol 1976;14:680-686.
18. Schiavo G, Benfenati F, Poulain B, et al. Tetanus and botulinum-B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin. Nature 1992;359:832-835.
19. Sakaguchi G. Clostridium botulinum toxins. Pharmacol Ther 1983;19:165-194.
20. Siegel LS. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid. J Clin Microbiol 1989;27:1906-1908.
21. Consky E, Basinski A, Belle L, Ranawaya R, Lang A. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) [abstract]. Neurology 1990;40(suppl 1):445.
22. Consky ES, Lang AE. Clinical assessments of patients with cervical dystonia. In: Jankovic J, Hallet M, eds. Therapy with botulinum toxin. New York: Marcel Dekker, 1994:224-226.
23. de Bruin AF, de Witte LP, Stevens F, Diederiks JP. Sickness Impact Profile: the state of the art of a generic functional status measure. Soc Sci Med 1992;35:1003-1014.
24. SAS Institute Inc. "PROC GLM" in SAS/STAT© User's Guide, Version 6. 4th ed. Vol. 2. Cary, NC: SAS Institute, 1989:891-996.
25. SAS Institute Inc. "PROC FREQ" in SAS/STAT© User's Guide, Version 6, 4th ed., vol. 1. Cary, NC: SAS Institute, 1989:851-889.
26. Truong D, Cullis P, O'Brien C, Koller M, Garces A, Wallace JD. BotB™ (botulmum toxin type B) is safe and well tolerated in botulinum toxin type A-resistant cervical dystonia patients [abstract]. Mov Disord 1995;10(3):394.
27. Cullis PA, O'Brien CF, Troung DD, Koller M, Villegas TP, Wallace JD. BotB (botulinum toxin type B): an open label, dose escalation, safety and preliminary efficacy study in cervical dystonia patients [abstract]. 3rd International Dystonia Symposium. Mov Disord 1997;12:26.
28. American BotB™ Cervical Dystonia (ABCD) Study Group. BotB (botulinum toxin type B) in the treatment of cervical dystonia - protocol AN072-008: an interim analysis [abstract]. Mov Disord 1995;10:372.
29. Tsui JKC, Haward M, Mak EJM, Schulzer M. Botulinum toxin type B in the treatment of cervical dystonia: a pilot study. Neurology 1995;45:2109-2110.
30. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG. Botulinum toxin for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 1992;42:878-882.
31. Consky E, Basinski A, Belle Scantlebury L, Lang AE. Comparison of botulinum toxin treatment variables for spasmodic torticollis [abstract]. Neurology 1991;41(suppl 1):273.
32. Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 1997;12: 100-102.